Sihuan Pharmaceutical Holdings Group Dirección

Dirección controles de criterios 3/4

El CEO de Sihuan Pharmaceutical Holdings Group's es Weicheng Guo , nombrado en Oct 2014, tiene una permanencia de 9.5 años. compensación anual total es CN¥3.15M, compuesta por 100% salario y 0% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.12% de las acciones de la empresa, por valor de HK$6.13M. La antigüedad media del equipo directivo y de la junta directiva es de 1.5 años y 8.1 años, respectivamente.

Información clave

Weicheng Guo

Chief Executive Officer (CEO)

CN¥3.0m

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	9.7yrs
Participación del CEO	0.1%
Permanencia media de la dirección	1.7yrs
Promedio de permanencia en la Junta Directiva	8.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Weicheng Guo en comparación con los beneficios de Sihuan Pharmaceutical Holdings Group?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	CN¥3m	CN¥3m	-CN¥54m
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥2b
Dec 31 2022	CN¥3m	CN¥3m	-CN¥2b
Jun 30 2022	n/a	n/a	-CN¥144m
Mar 31 2022	n/a	n/a	CN¥141m
Dec 31 2021	CN¥6m	CN¥6m	CN¥427m
Sep 30 2021	n/a	n/a	CN¥681m
Jun 30 2021	n/a	n/a	CN¥945m
Mar 31 2021	n/a	n/a	CN¥727m
Dec 31 2020	CN¥6m	CN¥6m	CN¥508m
Sep 30 2020	n/a	n/a	-CN¥14m
Jun 30 2020	n/a	n/a	-CN¥537m
Mar 31 2020	n/a	n/a	-CN¥2b
Dec 31 2019	CN¥6m	CN¥6m	-CN¥3b
Sep 30 2019	n/a	n/a	-CN¥2b
Jun 30 2019	n/a	n/a	-CN¥1b
Mar 31 2019	n/a	n/a	CN¥238m
Dec 31 2018	CN¥6m	CN¥6m	CN¥2b
Sep 30 2018	n/a	n/a	CN¥1b
Jun 30 2018	n/a	n/a	CN¥1b
Mar 31 2018	n/a	n/a	CN¥1b
Dec 31 2017	CN¥6m	CN¥6m	CN¥1b

Compensación vs. Mercado: La compensación total ($USD434.74K) de Weicheng está en línea con el promedio de empresas de tamaño similar en el mercado Hong Kong ($USD520.90K).

Compensación vs. Ingresos: La compensación de Weicheng ha sido consistente con los resultados de la empresa en el último año.

CEO

Weicheng Guo (60 yo)

9.7yrs

Permanencia

CN¥3,000,000

Compensación

Dr. Weicheng Guo co-founded Sihuan Pharmaceutical Holdings Group Ltd. and has been its Chief Executive Officer since October 20, 2014. Dr. Guo is responsible for the overall operations of Sihuan Pharmaceut...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Fengsheng Che	Co-Founder & Executive Chairman	18.1yrs	CN¥7.00m	5.36% CN¥ 278.6m
Weicheng Guo	Deputy Chairman & CEO	9.7yrs	CN¥3.00m	0.12% CN¥ 6.4m
Guili Miao	Deputy CEO	1.7yrs	CN¥5.05m	sin datos
Jionglong Zhang	Executive Director	3.6yrs	CN¥646.00k	2.14% CN¥ 111.4m
Yanling Chen	Joint Company Secretary & Executive Director	1.7yrs	CN¥1.77m	sin datos
Kin Wai Li	Joint Company Secretary	1.7yrs	sin datos	sin datos
Xianhui Meng	Deputy General Manager	no data	CN¥4.26m	sin datos

1.7yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 460 no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Fengsheng Che	Co-Founder & Executive Chairman	18.1yrs	CN¥7.00m	5.36% CN¥ 278.6m
Weicheng Guo	Deputy Chairman & CEO	18.1yrs	CN¥3.00m	0.12% CN¥ 6.4m
Guili Miao	Deputy CEO	1.7yrs	CN¥5.05m	sin datos
Jionglong Zhang	Executive Director	6.2yrs	CN¥646.00k	2.14% CN¥ 111.4m
Yanling Chen	Joint Company Secretary & Executive Director	6.2yrs	CN¥1.77m	sin datos
Wah Kwong Tsang	Independent Non-Executive Director	10.8yrs	CN¥371.00k	sin datos
Xun Zhu	Independent Non-Executive Director	10.3yrs	CN¥371.00k	sin datos
Guan Wang	Independent Non-Executive Director	1.2yrs	CN¥202.00k	sin datos

8.3yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de 460 se considera experimentada (8.1 años de antigüedad promedio).

Sihuan Pharmaceutical Holdings Group Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Deputy General Manager recently bought HK$19m worth of stock

Recent updates

New major risk - Revenue and earnings growth

Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA

Now 21% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Upcoming dividend of HK$0.037 per share

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Upcoming dividend of HK$0.13 per share

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Full year 2021 earnings released: EPS: CN¥0.044 (vs CN¥0.054 in FY 2020)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

Investor sentiment improved over the past week

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020)

Non-Executive Director Jin-ha Kim has left the company

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.016 per share

Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends

Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019)

Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: HK$2.68

Sihuan Pharmaceutical Holdings Group Ltd. Announces Selection of its Pantoprazole Sodium Injection (Panzuoer® 40mg per unit) and Ibuprofen Injection (Falanfen® 4ml: 0.4g, Tenaan® 8ml: 0.8g) in the Fourth Batch of National Drug Centralized Procurement

Sihuan Pharmaceutical Holdings Group Ltd. Announces Cinepazide Maleate Injection Obtain Approval from the National Medical Products Administration

New 90-day high: HK$1.32

Upcoming Dividend of HK$0.035 Per Share

Sihuan Pharmaceutical Holdings Group Ltd.(SEHK:460) dropped from FTSE All-World Index (USD)

First half earnings released

Deputy General Manager recently bought HK$19m worth of stock

Earnings released

New 90-day high - HK$1.03

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación